Inventor · disambiguated record
Thomas P. Bobinski
Also filed as: BOBINSKI THOMAS · BOBINSKI THOMAS P
11 granted patents·7 pending applications·23 citations·filing 2018–2025
85Inventor score
Top patents by PatentIndex Score
18 records- 0196US11091495B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Aug 17, 2021·4 cites·26 claims
- 0292US11220509B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·2 cites·27 claims
- 0391US10647715B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted May 12, 2020·10 cites·9 claims
- 0486US10266542B2EZH2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 23, 2019·6 cites·40 claims
- 0584US11479551B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Oct 25, 2022·1 cites·30 claims
- 0682US2025282787A1SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORSMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0780US12371435B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·20 claims
- 0872US2023054883A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0968US11912719B2Substituted isoquinolines as rock kinase inhibitorsCervello Therapeutics LLC·Filed 2021·Granted Feb 27, 2024·0 cites·13 claims
- 1068US11492351B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·0 cites·27 claims
- 1168US2020262837A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1266US11485738B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·18 claims
- 1364US12037357B2Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cellsDECIDUOUS THERAPEUTICS INC·Filed 2023·Granted Jul 16, 2024·0 cites·18 claims
- 1459US11248004B2Substituted isoquinolines as rock kinase inhibitorsCervello Therapeutics LLC·Filed 2020·Granted Feb 15, 2022·0 cites·17 claims
- 1559US2025092078A1Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cellsDECIDUOUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1659US2020308170A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1757US2024208912A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1850US2025381206A1Invariant natural killer t-cell activatorsDECIDUOUS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas P. Bobinski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →